Zura Bio (NASDAQ: ZURA) has appointed Sandeep Kulkarni, MD, as chief executive officer (CEO), effective today.
Dr. Kulkarni will continue to serve as a director of Zura. He succeeds Kim Davis, JD, who has served as Interim CEO since October 2025 following the commencement of a medical leave of absence by CEO Robert Lisicki. Mr. Lisicki is resigning as CEO and as a director, effective today. Ms. Davis will continue in her roles as COO, CLO, and corporate secretary.
In a statement, Amit Munshi, chairman of Zura’s BOD, commented, “We are honored to have Sandeep lead Zura as we enter this important period for our company, with two potentially transformative readouts over the next 18 months. He brings a strong combination of scientific, operational, and strategic leadership. His service on our board has provided him with a strong understanding of our programs and their transformative potential, positioning him well to lead Zura.”
